Baylor Genetics RNA Sequencing Studies Show 24% Diagnostic Success Rate for Previously Undiagnosed Rare Diseases
核心洞察
Baylor Genetics (搜索) presented research at the American Society of Human Genetics (搜索) 2025 Annual Meeting demonstrating RNA sequencing (搜索)'s ability to reclassify half of eligible variants from genome and exome sequencing cases.
A study of 45 previously undiagnosed patients using whole transcriptome (搜索) RNA sequencing (搜索) achieved a 24% diagnostic success rate, providing molecular diagnoses in 11 cases.
RNA sequencing (搜索) identified pathogenic mechanisms that DNA-based methods had not detected, particularly benefiting cases with noncoding variants that would be missed by exome sequencing alone.
Baylor Genetics (搜索) has unveiled compelling new research demonstrating the clinical utility of RNA sequencing (搜索) in diagnosing rare diseases (搜索), with studies showing significant improvements in diagnostic success rates for previously undiagnosed patients. The findings were presented at the American Society of Human Genetics (搜索) 2025 Annual Meeting in Boston, highlighting the transformative potential of multi-omic approaches in precision diagnostics.
RNA Sequencing Reclassifies Half of Eligible Variants
In the first study titled "Diagnostic Utility of RNA Sequencing (搜索) for Reclassification of Rare Disease Variants by Exome and Genome Sequencing," researchers analyzed 3,594 consecutive cases to evaluate RNA sequencing's ability to provide functional evidence for more accurate variant classification. The comprehensive analysis identified variants from genome and exome sequencing that met eligibility criteria for targeted RNA sequencing across a wide spectrum of diseases and inheritance patterns.
The results demonstrated that RNA sequencing (搜索) successfully reclassified half of the eligible variants identified, providing critical clarity on these findings. This reclassification capability represents a significant advancement in genetic diagnostics, as variants of uncertain significance (搜索) often leave patients and clinicians without definitive answers.
The study also revealed important technical considerations, noting that some genes had low Transcripts Per Million (TPM), which highlighted test sensitivity limitations. Despite these challenges, the overall utility of RNA sequencing (搜索) in establishing rare disease diagnoses strongly supports its inclusion alongside other multi-omic approaches in clinical genome and exome sequencing protocols.
Noncoding Variants Reveal Hidden Diagnostic Opportunities
A particularly noteworthy finding emerged regarding noncoding variants, which are often overlooked in traditional genetic testing approaches. The research showed that over one-third of RNA sequencing (搜索)-eligible cases contained noncoding variants identified through genome sequencing that would likely have been missed if exome sequencing alone had been ordered. This discovery underscores the importance of comprehensive genomic approaches in rare disease diagnostics.
Transcriptome Sequencing Achieves 24% Diagnostic Success Rate
The second study, "Clinical Utility of Transcriptome (搜索) RNA-Sequencing in Diagnosing Rare Genetic Disorders (搜索): Initial Experiences," provided even more compelling evidence of RNA sequencing (搜索)'s diagnostic power. Working in collaboration with the Undiagnosed Diseases Network (搜索), researchers enrolled 45 patients with previously undiagnosed clinical presentations spanning multiple medical specialties.
Using validated whole transcriptome (搜索) RNA sequencing (搜索) (TxRNA-seq), the research team achieved a 24% diagnostic success rate, providing positive diagnostic results in 11 out of 45 cases. The technology uncovered pathogenic mechanisms through direct transcript-level assessment that DNA-based methods had failed to detect, representing a significant breakthrough for patients who had exhausted traditional diagnostic approaches.
Clinical Impact and Future Implications
According to Christine Eng, M.D., Chief Medical Officer and Chief Quality Officer at Baylor Genetics (搜索), "RNA sequencing (搜索) is unlocking a new era of precision diagnostics, one that allows us to see what was previously unclear. By harnessing the full potential of multi-omics technologies, including RNA sequencing, we are helping to uncover the underlying causes of rare and undiagnosed diseases, often when traditional methods fall short."
The research team's initial clinical experience underscores the application of transcriptome (搜索) RNA sequencing (搜索) to identify previously unknown findings, which improves diagnostic yield and refines molecular interpretations in complex rare disease cases. This advancement is particularly significant for patients and families who have endured lengthy diagnostic odysseys without answers.
Advancing Multi-Omic Diagnostic Approaches
The findings support the integration of RNA sequencing (搜索) and other multi-omic technologies into standard clinical practice for rare disease diagnostics. The ability to reclassify variants of uncertain significance (搜索) and identify pathogenic mechanisms missed by DNA-based methods represents a substantial step forward in precision medicine.
Baylor Genetics (搜索)' research demonstrates that combining traditional genome and exome sequencing with RNA sequencing (搜索) provides a more comprehensive diagnostic approach, potentially ending the diagnostic odyssey for many patients with rare and undiagnosed diseases. The company's work contributes to the growing body of evidence supporting multi-omic approaches in clinical genomics, offering new hope for patients and families seeking answers to complex genetic conditions.